TREATING TOBACCO DEPENDENCE: AN INTEGRAL PART OF PULMONARY CLINICAL PRACTICE

Similar documents
Counseling the Tobacco Dependent Patient. Gretchen Whitby, CNP The Lung Center

MYTH #1. Nicotine is a harmful, medically dangerous drug. Nicotine: Myths, Realities & Treatment OBJECTIVES FACT. CSAM Board Review Course, 10/23/08

SMOKING CESSATION WORKSHOP. Dr Mark Palayew December

Introduction to pharmacotherapy

TWIN VALLEY BEHAVIORAL HEALTHCARE CLINICAL GUIDELINES FOR MANAGEMENT OF SMOKING CESSATION

Nicotine Replacement and Smoking Cessation: Update on Best Practices

EVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO

Tobacco Use Dependence and Approaches to Treatment

Wanting to Get Pregnant

Smoking Cessation. Disclosures. Thank You. None

Effective Treatments for Tobacco Dependence

Over the Road Truck Driver Who Smokes

How to help your patient quit smoking. Christopher M. Johnson MD, PhD

Integrating Tobacco Cessation into Practice

Executive Summary. Context. Guideline Origins

Pharmacotherapy for Tobacco Dependence Treatment

Tobacco & Nicotine: Addiction and Treatment

3. Chantix [package insert]. New York, NY: Pfizer, Inc,; Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine

Tobacco Cessation: Best Practices in Cancer Treatment. Audrey Darville, PhD APRN, CTTS Certified Tobacco Treatment Specialist UKHealthCare

You Can Make a Difference!

Why Tobacco Cessation?

RECOMMENDATIONS FOR HEALTH CARE PROVIDERS

Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions

Health Promotion Research: Smoking Cessation. Paula Sawyer

Tobacco Dependence Assessment and Treatment

PHD THESIS STUDY ON THE USE OF THE PHARMACOLOGIC THERAPY WITH BUPROPION ON TOBACCO ABSTINENCE FOR SMOKERS WITH HIGH NICOTINE DEPENDENCE

Smoking Cessation: Treating Tobacco Dependence

HIV and Aging. Making Tobacco Cessation a Priority in HIV/AIDS Services. Objectives. Tobacco Use Among PLWHA

Pharmacotherapy for Treating Tobacco Dependence

E-CIGARETTE OR DRUG DELIVERY DEVICE?

Best Practices in Tobacco Treatment IDN

Smoking Cessation for Persons with Serious Mental Illness

A systems approach to treating tobacco use and dependence

Medication Management to Aid in Smoking Cessation. Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019

PHARMACOTHERAPY OF SMOKING CESSATION

Smoking Cessation Strategies for the 21st Century

Population-level Strategies to Prevent and Reduce Tobacco Use Success and Challenge

Smoking Cessation: Where Are We Now? Nancy Rigotti, MD

Treating Tobacco Use:

Stop. Stop before your op. Living. Start. Helping you cut out smoking for good. NHS Foundation Trust

The 5A's are practice guidelines on tobacco use prevention and cessation treatment (4):

Treating Tobacco Use and Dependence

STOP SMOKING with Nicotine Replacement Therapy

Update on Medications for Tobacco Cessation

Fast Facts. Morbidity and Mortality (Related to Tobacco Use)

Clearing the Air: What You Need to Know and Do to Prepare to Quit Smoking. Getting Ready to Quit Course

Nicotine: A Powerful Addiction

The Interaction of Depression and Smoking following ACS Andrew M. Busch, PhD

Smoking Cessation Strategies: What Works?

MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE

Health Risks Posed by Smoking

Tobacco Dependence: Assessment and Treatment. Douglas Arenberg

The Vancouver General Hospital Smoking Cessation Clinic: Outcomes from a Specialist Cessation Service within Cardiology

TOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS

Asthma Care in tribal Communities:

Evidence-based Practice

Linda Sarna, RN, DNSc, FAAN. Marjorie Wells, PhD, RN, FNP

Pharmacotherapy Safety and Efficacy in Adolescent Smoking Cessation

Adolescents and Tobacco Cessation

TRENDS IN TOBACCO UNDERSTAND 5/26/2017 LEARNING OBJECTIVES. Understand the types of tobacco products trending in today s market & associated risks

Pharmacologic Therapy for Tobacco Use & Dependence

ASSISTING PATIENTS with QUITTING EFFECTS OF CLINICIAN INTERVENTIONS. The 5 A s. The 5 A s (cont d)

19 INSTRUCTOR GUIDELINES

Smoking Cessation Counselling

Smoking Cessation Counselling

Smoking Cessation. MariBeth Kuntz, PA-C Duke Center for Smoking Cessation

Helping Employees Break the Habit

9 INSTRUCTOR GUIDELINES

Developing Genetic Education for Smoking Cessation. Julia F. Houfek, PhD, APRN-CNS, BC Associate Professor UNMC College of Nursing

Faculty Disclosure. Objectives. Lung Cancer in Kentucky: Improving Patient Outcomes 10/28/16. Lung Cancer Burden in Kentucky

Integrated Cardiopulmonary Pharmacology Third Edition

Clearing the Air: What You Need to Know and Do to Prepare to Quit Smoking

Collaborating to help Oregon tobacco users quit

Be Tobacco-Wise. Learn about the benefits of quitting smoking. Reasons to be Smoke-Free

TOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS

Comprehensive Smoking Cessation Programs

7 DAY QUIT SMOKING CHALLENGE 7 DAY QUIT SMOKING CHALLENGE 7 DAY QUIT SMOKING PDF YOU CAN QUIT SMOKING. QUIT SMOKING CDC 1 / 5

Helping People Quit Tobacco

Supplementary Online Content

RI Health Plan 2018 Annual Report Form on Tobacco Cessation Benefits

State of Behavioral Health. The Arizona Initiative for Tobacco Free Living in Individuals with Behavioral Health Disorders

Smoking Cessation: Nurse Interventions and Effective Programs

The Quit Clinic As an Anti-smoking Advocacy Tool

TOBACCO TREATMENT INPATIENT QUALITY MEASURES. Kathy Wonderly RN, MSEd, CPHQ Consultant Developed: December 2015

QUIT TODAY. It s EASIER than you think. DON T LET TOBACCO CONTROL YOUR LIFE. WE CAN HELP.

Smoking Cessation. May

Disclaimers. Smoking and Smoking Cessation. Worldwide. Objectives. Statistics at Home. Smoking Epidemic 16/10/2017

All information is based on scientific research about what will give you the best chances of quitting.

Smoking Cessation Strategies in 2017

NCDs Risk Factor No. 3 - Smoking. Commonwealth Nurses Federation

What is Quitline Iowa?

Smoking. know the facts

5. Offer pharmacotherapy to all smokers who are attempting to quit, unless contraindicated.

ALL QUITLINE FACTS: An Overview of the NAQC 2009 Annual Survey of Quitlines

Smokeless Tobacco Cessation: Review of the evidence. Raymond Boyle, PhD Tobacco Summit 2007 MDQuit.org

CURRENT ISSUES IN TOBACCO CESSATION FOR THE PRACTICING PHYSICIAN

How to Design a Tobacco Cessation Insurance Benefit

An Evolving Perspective on Smoking Cessation Therapies

For more information about quitting smoking, contact:

Addiction and Dependence

Transcription:

TREATING TOBACCO DEPENDENCE: AN INTEGRAL PART OF PULMONARY CLINICAL PRACTICE DAVID P. L. SACHS, MD DIRECTOR PALO ALTO CENTER FOR PULMONARY DISEASE PREVENTION PALO ALTO, CA Dr. Sachs has an active pulmonary medical practice and directs the small, independent, non-profit medical research and educational organization, The Palo Alto Center for Pulmonary Disease Prevention that he founded in 1985. Since tobacco dependence directly causes 90% of all pulmonary diseases and is the leading cause of death in the United States, accounting for 18% of all hospital deaths and nearly 10% of all health-care costs, Dr. Sachs has focused on developing and implementing effective and clinically relevant and scalable tobacco-dependence treatments. He has incorporated effective tobacco-dependence treatment as part of his regular pulmonary practice since 1983. Since 2006, he has Chaired the American College of Chest Physicians (ACCP) Tobacco- Dependence Treatment Committee. With his committee of 5 other pulmonary specialists and clinicians who had also incorporated treatment for tobacco dependence as part of regular pulmonary medical care they developed the first tobacco-dependence treatment guideline to also incorporate clinical experience and consensus recommendations (available free at http://tobaccodependence.chestnet.org). The ACCP used the same procedures as the NHLBI in developing its asthma diagnosis and treatment guidelines. Dr. Sachs received his MD from Stanford University in 1972 and completed a 3-year fellowship in Pulmonary and Critical Care Medicine there in 1976, finishing his Internal Medicine residency at University Hospitals of Cleveland in 1978. He has designed and conducted more than 30 tobaccodependence clinical treatment trials to date, including studies funded by the NIH, NIDA, and other non-profit health organizations. He has published over 85 peer-reviewed, scientific articles, invited editorials, and books. The Palo Alto Center for Pulmonary Disease Prevention is now developing 1-, 3-, and 5-day, intensive, on-site, clinical training programs to enable practicing physicians and nurses to effectively diagnose and treat tobacco dependence as a part of regular medical practice. The Center is also developing programs to enable all medical schools to fully train all Year-1 through Year 4 & all PGY1 residents in the basic science and practical clinical treatment of tobacco dependence, including experience with Standardized Patients. He and professional colleague, Bonnie L. Sachs, RN, MSN, who is also wife, have a 32-year-old son who, is certified air traffic controller at San Francisco Intentional Airport and guided my flight out to Phoenix yesterday. David and his wife also have an amazingly curious, and scientifically minded, 18-month-old Golden Retriever puppy. Ask me about some of the test-retest experiments this puppy has recently conducted! 1

OBJECTIVES: Participants should be better able to: 1. Examine & review tobacco use as a chronic medical disease 2. Explain why tobacco use is not a habit and does not constitute a character flaw 3. Recommend the basic approach, particularly the Step-Wise Approach to Tobacco-Dependence Therapy, contained in the American College of Chest Physicians Tobacco-Dependence Treatment Tool Kit. 3 rd Ed. (published June 2010) guidelines (http://tobaccodependence.chestnet.org), for effectively treating tobacco dependence 4. Examine diagnostic instruments to determine severity of tobacco dependence and to monitor treatment effectiveness THURSDAY, MARCH 12, 2015 11:30 AM 2

Tobacco-Dependence Treatment as a Focus of Clinical Practice Presented by David P.L. Sachs, MD Director, Palo Alto Center for Pulmonary Disease Prevention & Chair, Tobacco-Dependence Treatment Tool Kit Committee, 3rd Ed. American College of Chest Physicians & Attending Physician and Teaching Faculty Pulmonary & Critical Medicine Stanford University Medical Center PHONE: 650-833-7994 WEB: www.drlung.com NAMDRC 38th Annual Meeting & Educational Conference The FireSky Resort Scottsdale, AZ Thursday, 3/12/2015, 11:30 AM 12:15 AM DISCLOSURE Dr. Sachs has declared no conflicts of interest related to the content of his presentation. CHEST 2011: Stepwise Approach to Pharmacologic Management of Tobacco-Dependence 10/24/11 David P.L. Sachs, MD 3 2

Presenter Disclosures David P.L. Sachs, MD Part 1: Personal financial relationships with commercial interests relevant to this presentation during the past 12 months, including e-cigarettes: None Part 2: Personal financial relationships with non-commercial interests relevant to this presentation during the past 12 months: None Part 3: Relevant institutional financial interests: None Part 4: Personal financial relationships with tobacco industry entities within the past 3 years: None Part 5: Off-Label Disclosure: Presentation will include discussion of off-label use, but use which is consistent with the findings and recommendations of: American College of Chest Physicians Tobacco-Dependence Treatment Tool Kit, 3rd Ed., June 2010. Fiore MC, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008. David P.L. Sachs, MD-3/12/2015 Palo Alto Center for Pulmonary Disease Prevention 3 Sign-Up Sheets For my slide-set, including slides I didn t have time to present today, other materials and patient monitoring tools, and notices of future educational training programs to improve your clinical skills to effectively treat tobacco dependence as part of your clinical practice: Enter your» Name» E-Mail» Office Phone (I need this if my e-mail to you bounces back as Not Deliverable, so that we can correct your e-mail address) On 1 of the 20 sheets in this room Please leave these sheets where you found them; I shall collect them during our lunch break. David P.L. Sachs, MD-2/25/2015 Palo Alto Center for Pulmonary Disease Prevention 4 4

Goals Background A Tale of Two Cases Neurobiology of Nicotine Addiction ACCP Tobacco-Dependence Treatment Tool Kit, 3rd Ed., 2010 How to Enable You to Effectively Treat Tobacco Dependence as a Focus of Your Clinical Pulmonary Practice Correct Coding to Enable Normal, Fair, & Reasonable Reimbursement David P.L. Sachs, MD 5 6

Goals (cont.) If You Can Treat Asthma or ILD You Can Treat Tobacco Dependence If You Now Obtain 3 rd -Party Reimbursement for Asthma or COPD Patient Care You Can Obtain Identical Reimbursement for Tobacco- Dependence Care David P.L. Sachs, MD 7 Question: What Is The Leading Cause of Death in the World & also in the United States Today? 1. COPD 2. Coronary Heart Disease 3. Tobacco Dependence 4. HIV/AIDS 5. TB David P.L. Sachs, MD 8 6

What is the leading cause of death in the world and also in the United States today? 1. COPD 2. Coronary Heart Disease 3. Tobacco Dependence 4. HIV/AIDS 5. TB 41% 56% 2% 0% 0% 1. 2. 3. 4. 5. Tobacco dependence is the leading cause of death in the world today Topping Malaria, HIV/AIDS & TB combined! Source: 1) WHO. WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER Package. Geneva: World Health Organization, 2008, p. 8. (http://www.who.int/tobacco/mpower/en/) David P.L. Sachs, MD 10 7

8

9

Tobacco Dependence Is a Fatal Disease 1 Killing 50% of Its Victims 2 50% die in middle age 3 Lose 20-25 yrs life expectancy 3 1 CDC. Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses: United States, 2000-2004. MMWR 2008 (Nov 14);57(45):1226-1228. 2 Doll R, et al. Mortality in Relation to Smoking. BMJ 1994;309(6959):901-911. 3 The President s Cancer Panel. 2006-2007 Annual Report. Executive Summary. Rockville, MD: US Dept of Health & Human Services. NIH, NCI. 2008:i-xx; see especially pp. vii. (http://deainfo.nci.nih.gov/advisory/pcp/annualreports/pcp07rpt/execsum.pdf) David P.L. Sachs, MD 15 Tobacco Dependence Is the most important chronic medical disease you never learned about in medical school! David P.L. Sachs, MD 16 10

Dr. Sachs s Tobacco-Dependence Experience Since 1985 >30 Clinical Trials American Heart Association-funded American Lung Association-funded NIH/NIDA-funded Pharmaceutical Industry Funded Most randomized, double-blind, placebocontrolled Personally treated >7,500 tobaccodependent patients my pulmonary medicine practice David P.L. Sachs, MD 17 Inpatient Case #1 51 y/o male admitted because of compound femoral fracture Admission urinalysis shows 4+ glucose and 2+ protein Admission, random blood glucose = 400 David P.L. Sachs, MD 18 11

What Would You Do to Manage His Diabetes? 1. Nothing not appropriate to initiate inhospital treatment for a problem not related to the cause of admission. 2. Initiate work-up of cause of hyperglycemia, glycosuria, and proteinuria. 3. Initiate in-hospital education for him and his family about diabetes and its management. 4. #2 and #3, only. 5. Something different. David P.L. Sachs, MD 19 What would you do to manage his Diabetes? 1. Nothing not appropriate to initiate inhospital treatment for a problem not related to the cause of admission 2. Initiate work-up of cause of hyperglycemia 3. Initiate in-hospital education for him and his family about diabetes and its management. 4. #2 and #3 Only. 5. Something different. 81% 14% 2% 2% 0% 1. 2. 3. 4. 5. 12

Inpatient Case #2 59 y/o female admitted because of difficult to control diabetes When you take her HPI, you also discover that she smokes 1-2 packs/day David P.L. Sachs, MD 21 What Would You Do to Manage Her Tobacco Dependence? 1. Nothing not appropriate to initiate inhospital treatment for a problem not related to the cause of admission. 2. Advise her in firm, unequivocal language to quit smoking. 3. Assess if she is willing to make a quit attempt while in the hospital. 4. Diagnose the severity of her tobacco dependence. 5. Something different. David P.L. Sachs, MD 22 13

What would you do to manage her tobacco dependence? 1. Nothing not appropriate to initiate inhospital treatment for a problem not related to the cause of admission 2. Advise her in firm, unequivocal language to quit smoking 3. Assess if she is willing to make a quit attempt while in the hospital 4. Diagnose the severity of her tobacco dependence. 5. Something different 1. 56% 17% 17% 11% 0% 2. 3. 4. 5. The Fagerström Test for Nicotine Dependence (FTND) 6-item, physiologically validated questionnaire Linear scale from 0 to 10 points 0 means no physiological dependence on nicotine 10 means severe physiological dependence on nicotine Source: Heatherton TF, et al. Brit J Addict 1991; 86:1119-1127. David P.L. Sachs, MD 24 14

The Fagerström Test for Nicotine Dependence (FTND) Physiologically validated Easy to use in a hospital or outpatient setting Linear scale from 0 to 10 points 0 means no physiological dependence on nicotine 10 means severe physiological dependence on nicotine Low Nicotine Dependence 0-4 points High Nicotine Dependence 5-10 points Source: Heatherton TF, et al. Brit J Addict 1991; 86:1119-1127. David P.L. Sachs, MD 26 15

How Can You Diagnose Severity of Her Tobacco Dependence? Measure her FTND 1 Measure the severity of her Nicotine Withdrawal Symptoms 2,3 While smoking, pre-admission While not smoking, now, in-hospital Sources: 1 Heatherton TF, et al. Brit J Addict 1991; 86:1119-1127. 2 Hughes JR, et al. Psychopharmacol 1984. 83:82-87. 3 Hatsukami DK, et al. Psychopharmacol 1984. 84:231-236. David P.L. Sachs, MD 27 What Two Assessments Enable You to Best Anticipate the Intensity and Duration of Tobacco-Dependence Treatment for Your Patient? 1. Whether or not your patient wants to stop smoking. 2. The number of cigarettes/day your patient smoked pre-hospital admission. 3. The FTND score. 4. The Nicotine Withdrawal Symptom Score. 5. Random Serum Cotinine level. David P.L. Sachs, MD 28 16

What two assessments enable you to best anticipate the intensity and duration of tobacco-dependence treatment for your patient? 1. Whether or not your patient wants to stop smoking. 2. The number of cigarettes/day your patient smoked pre-hospital admission 3. The FTND score. 4. The Nicotine Withdrawal Symptom Score. 5. Random Serum Continine level. 35% 33% 15% 13% 5% 1. 2. 3. 4. 5. Biology of Nicotine Addiction APHA 2012 14 th Annual Pre-Conference CBPHC Workshop 10/27/12 David P.L. Sachs, MD 30 17

31 18

Current Standard of Care At least 2 or more medications odds of stopping smoking 50%-100% 4x-6x improvement compared to no medication Sources: 1) Fiore MC, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Dept of Health & Human Services. Public Health Service. May 2008. (www.surgeongeneral.gov/tobacco/default.htm) 2) American College of Chest Physicians. Tobacco-Dependence Treatment Tool Kit, 3 rd Ed. Northbrook, IL: ACCP. June 2010. (http://tobaccodependence.chestnet.org) David P.L. Sachs, MD 34 19

LLU-SM, Department of Medicine, ACP-Master Medical Grand Rounds-9/1/10 3 5 PARADIGM SHIFT David P.L. Sachs, MD 36 20

21

Classification of Severity Table #I CLASSIFY TOBACCO-DEPENDENCE SEVERITY Clinical Features Before Treatment* Cigarette Use Nicotine Withdrawal Symptoms Quantitative Health Status STEP 4 Very Severe >40 cigs/day NWS >40 FTND 8-10 1 Chronic Medical Dis., AND/OR 1 Psychiatric Disease STEP 3 Severe 20-40 cigs/day NWS 31-40 FTND 6-7 1 Chronic Medical Dis., OR 1 Psychiatric Disease STEP 2 Moderate 6-19 cigs/day NWS 21-30 FTND 4-5 STEP 1 Mild 1-5 cigsday NWS 11-20 FTND 2-3 STEP 0 Non-Daily/Social Non-daily cigarette use NWS <10 FTND 0-1 *The presence of one feature of severity is sufficient to place patient in that category. CPD=Cigarettes Per Day Time To 1 st Cig=Time To First Cigarette after Awakening in the Morning NWS=Nicotine Withdrawal Symptom Score FTND=Fagerström Test for Nicotine Dependence Score Se=Serum Cotinine=First-pass, hepatic metabolite of nicotine; physiologically inactive ACCP Tobacco-Dependence Treatment Tool Kit, 3 rd Ed., 2010 I Copyright 2009-2010 American College of Chest Physicians Classification of Severity Table #I CLASSIFY TOBACCO-DEPENDENCE SEVERITY Clinical Features Before Treatment* Cigarette Use Nicotine Withdrawal Symptoms Quantitative Health Status STEP 4 Very Severe >40 cigs/day NWS >40 FTND 8-10 1 Chronic Medical Dis., AND/OR 1 Psychiatric Disease STEP 3 Severe 20-40 cigs/day NWS 31-40 FTND 6-7 1 Chronic Medical Dis., OR 1 Psychiatric Disease STEP 2 Moderate 6-19 cigs/day NWS 21-30 FTND 4-5 STEP 1 Mild 1-5 cigsday NWS 11-20 FTND 2-3 STEP 0 Non-Daily/Social Non-daily cigarette use NWS <10 FTND 0-1 *The presence of one feature of severity is sufficient to place patient in that category. CPD=Cigarettes Per Day Time To 1 st Cig=Time To First Cigarette after Awakening in the Morning NWS=Nicotine Withdrawal Symptom Score FTND=Fagerström Test for Nicotine Dependence Score Se=Serum Cotinine=First-pass, hepatic metabolite of nicotine; physiologically inactive ACCP Tobacco-Dependence Treatment Tool Kit, 3 rd Ed., 2010 I Copyright 2009-2010 American College of Chest Physicians 22

Classification of Severity Table #I CLASSIFY TOBACCO-DEPENDENCE SEVERITY Clinical Features Before Treatment* Cigarette Use Nicotine Withdrawal Symptoms Quantitative Health Status STEP 4 Very Severe >40 cigs/day NWS >40 FTND 8-10 1 Chronic Medical Dis., AND/OR 1 Psychiatric Disease STEP 3 Severe 20-40 cigs/day NWS 31-40 FTND 6-7 1 Chronic Medical Dis., OR 1 Psychiatric Disease STEP 2 Moderate 6-19 cigs/day NWS 21-30 FTND 4-5 STEP 1 Mild 1-5 cigsday NWS 11-20 FTND 2-3 STEP 0 Non-Daily/Social Non-daily cigarette use NWS <10 FTND 0-1 *The presence of one feature of severity is sufficient to place patient in that category. CPD=Cigarettes Per Day Time To 1 st Cig=Time To First Cigarette after Awakening in the Morning NWS=Nicotine Withdrawal Symptom Score FTND=Fagerström Test for Nicotine Dependence Score Se=Serum Cotinine=First-pass, hepatic metabolite of nicotine; physiologically inactive ACCP Tobacco-Dependence Treatment Tool Kit, 3 rd Ed., 2010 I Copyright 2009-2010 American College of Chest Physicians Classification of Severity Table #I CLASSIFY TOBACCO-DEPENDENCE SEVERITY Clinical Features Before Treatment* Cigarette Use Nicotine Withdrawal Symptoms Quantitative Health Status STEP 4 Very Severe >40 cigs/day NWS >40 FTND 8-10 1 Chronic Medical Dis., AND/OR 1 Psychiatric Disease STEP 3 Severe 20-40 cigs/day NWS 31-40 FTND 6-7 1 Chronic Medical Dis., OR 1 Psychiatric Disease STEP 2 Moderate 6-19 cigs/day NWS 21-30 FTND 4-5 STEP 1 Mild 1-5 cigsday NWS 11-20 FTND 2-3 STEP 0 Non-Daily/Social Non-daily cigarette use NWS <10 FTND 0-1 *The presence of one feature of severity is sufficient to place patient in that category. CPD=Cigarettes Per Day Time To 1 st Cig=Time To First Cigarette after Awakening in the Morning NWS=Nicotine Withdrawal Symptom Score FTND=Fagerström Test for Nicotine Dependence Score Se=Serum Cotinine=First-pass, hepatic metabolite of nicotine; physiologically inactive ACCP Tobacco-Dependence Treatment Tool Kit, 3 rd Ed., 2010 I Copyright 2009-2010 American College of Chest Physicians 23

Classification of Severity Table #I CLASSIFY TOBACCO-DEPENDENCE SEVERITY Clinical Features Before Treatment* Cigarette Use STEP 4 Very Severe STEP 3 Severe STEP 2 Moderate STEP 1 Mild Nicotine Withdrawal Symptoms Quantitative Health Status >40 cigs/day NWS >40 FTND 8-10 1 Chronic Medical Dis., AND/OR 1 Psychiatric Disease 20-40 cigs/day NWS 31-40 FTND 6-7 1 Chronic Medical Dis., OR 1 Psychiatric Disease 6-19 cigs/day NWS 21-30 FTND 4-5 1-5 cigsday NWS 11-20 FTND 2-3 NWS <10 FTND 0-1 STEP 0 Non-daily Non-Daily/Social cigarette use *The presence of one feature of severity is sufficient to place patient in that category. CPD=Cigarettes Per Day Time To 1st Cig=Time To First Cigarette after Awakening in the Morning NWS=Nicotine Withdrawal Symptom Score FTND=Fagerström Test for Nicotine Dependence Score Se=Serum Cotinine=First-pass, hepatic metabolite of nicotine; physiologically inactive ACCP Tobacco-Dependence Treatment Tool Kit, 3rd Ed., 2010 I Copyright 2009-2010 American College of Chest Physicians Question: What Tobacco-Dependence Diagnostic Severity Is This Patient? 1. Step 0, Non-Daily/Social 2. Step 1, Mild 3. Step 2, Moderate 4. Step 3, Severe 5. Step 4, Very Severe David P.L. Sachs, MD 24 44

What tobacco-dependence diagnostic severity is this patient? 1. Step 0, Non-daily/social 2. Step 1, Mild 3. Step 2, Moderate 4. Step 3, Severe 5. Step 4, Very Severe 56% 37% 4% 4% 0% 1. 2. 3. 4. 5. Classification of Severity Table #I CLASSIFY TOBACCO-DEPENDENCE SEVERITY Clinical Features Before Treatment* Cigarette Use Nicotine Withdrawal Symptoms Quantitative Health Status STEP 4 Very Severe >40 cigs/day NWS >40 FTND 8-10 1 Chronic Medical Dis., AND/OR 1 Psychiatric Disease STEP 3 Severe 20-40 cigs/day NWS 31-40 FTND 6-7 1 Chronic Medical Dis., OR 1 Psychiatric Disease STEP 2 Moderate 6-19 cigs/day NWS 21-30 FTND 4-5 STEP 1 Mild 1-5 cigsday NWS 11-20 FTND 2-3 STEP 0 Non-Daily/Social Non-daily cigarette use NWS <10 FTND 0-1 *The presence of one feature of severity is sufficient to place patient in that category. CPD=Cigarettes Per Day Time To 1 st Cig=Time To First Cigarette after Awakening in the Morning NWS=Nicotine Withdrawal Symptom Score FTND=Fagerström Test for Nicotine Dependence Score Se=Serum Cotinine=First-pass, hepatic metabolite of nicotine; physiologically inactive ACCP Tobacco-Dependence Treatment Tool Kit, 3 rd Ed., 2010 I Copyright 2009-2010 American College of Chest Physicians 25

Initial & Long-Term Tobacco-Dependence Medical Management Stepwise Approach to Tobacco-Dependence Treatment Adults (Based on the Asthma Model) Table #2 Outcome: Tobacco-Dependence Control No Nicotine Withdrawal Symptoms Controller: None Reliever: Not Known STEP 0: Non-Daily/Social Controller: Nicotine Patch or Bupropion-SR or Varenicline OR Reliever Meds: (NNS, NI, NG, NL)*, prn STEP 1: Mild Controller: Nicotine Patch or Bupropion-SR Reliever Meds: (NNS, NI, NG, NL)*, prn OR Controller: Varenicline, alone STEP 2: Moderate Controller(s): (1 or More) Varenicline Bupropion-SR Or Nicotine Patch Bupropion-SR Hi- Dose/Individualized Nicotine Patch Reliever Meds: (NNS, NI, NG, NL)*, prn STEP 3: Severe Multiple Controllers: Varenicline Bupropion-SR Hi-Dose Nicotine Patch Individualized Nicotine Patch Dose And Multiple Reliever Meds: (NNS, NI, NG, NL)*, prn STEP 4: Very Severe When tobacco dependence is controlled (patient is not smoking AND not suffering from nicotine withdrawal symptoms): Gradually reduce medications, one at a time Monitor, to maintain NO nicotine withdrawal symptoms STEP Down & Maintenance *Reliever Medications (Rapid Acting Nicotine Agonists): NNS=Nicotine Nasal Spray NI=Nicotine [Oral] Inhaler NG=Nicotine Gum NL= Nicotine Lozenge. Some patients will need indefinite use of Controller or Reliever Medications to maintain zero nicotine withdrawal symptoms and no cigarette use. ACCP Tobacco-Dependence Treatment Tool Kit, 3 rd Ed., 2010 I Copyright 2009-2010 American College of Chest Physicians Initial & Long-Term Tobacco-Dependence Medical Management Stepwise Approach to Tobacco-Dependence Treatment Adults (Based on the Asthma Model) Table #2 Outcome: Tobacco-Dependence Control No Nicotine Withdrawal Symptoms; then No Smoking Controller: None Reliever: Not Known STEP 0: Non-Daily/Social Controller: Nicotine Patch or Bupropion-SR or Varenicline OR Reliever Meds: (NNS, NI, NG, NL)*, prn STEP 1: Mild Controller: Nicotine Patch or Bupropion-SR Reliever Meds: (NNS, NI, NG, NL)*, prn OR Controller: Varenicline, alone STEP 2: Moderate Controller(s): (1 or More) Varenicline Bupropion-SR Or Nicotine Patch Bupropion-SR Hi- Dose/Individualized Nicotine Patch Reliever Meds: (NNS, NI, NG, NL)*, prn STEP 3: Severe Multiple Controllers: Varenicline Bupropion-SR Hi-Dose Nicotine Patch Individualized Nicotine Patch Dose And Multiple Reliever Meds: (NNS, NI, NG, NL)*, prn STEP 4: Very Severe When tobacco dependence is controlled (patient is not smoking AND not suffering from nicotine withdrawal symptoms): Gradually reduce medications, one at a time Monitor, to maintain NO nicotine withdrawal symptoms STEP Down & Maintenance *Reliever Medications (Rapid Acting Nicotine Agonists): NNS=Nicotine Nasal Spray NI=Nicotine [Oral] Inhaler NG=Nicotine Gum NL= Nicotine Lozenge. Some patients will need indefinite use of Controller or Reliever Medications to maintain zero nicotine withdrawal symptoms and no cigarette use. ACCP Tobacco-Dependence Treatment Tool Kit, 3 rd Ed., 2010 I Copyright 2009-2010 American College of Chest Physicians 26

Initial & Long-Term Tobacco-Dependence Medical Management Stepwise Approach to Tobacco-Dependence Treatment Adults (Based on the Asthma Model) Table #2 Outcome: Tobacco-Dependence Control No Nicotine Withdrawal Symptoms; then No Smoking Controller(s): Controller: Controller: Controller: None Reliever: Not Known STEP 0: Non-Daily/Social Nicotine Patch or Bupropion-SR Nicotine Patch or Bupropion-SR or Varenicline Reliever Meds: OR Reliever Meds: OR Controller: (NNS, NI, NG, NL)*, prn (NNS, NI, NG, NL)*, prn Varenicline, alone STEP 1: Mild STEP 2: Moderate (1 or More) Varenicline Bupropion-SR Or Nicotine Patch Bupropion-SR HiDose/Individualized Nicotine Patch Reliever Meds: (NNS, NI, NG, NL)*, prn STEP 3: Severe Multiple Controllers: Varenicline Bupropion-SR Hi-Dose Nicotine Patch Individualized Nicotine Patch Dose And Multiple Reliever Meds: (NNS, NI, NG, NL)*, prn STEP 4: Very Severe When tobacco dependence is controlled (patient is not smoking AND not suffering from nicotine withdrawal symptoms): Gradually reduce medications, one at a time Monitor, to maintain NO nicotine withdrawal symptoms STEP Down & Maintenance *Reliever Medications (Rapid Acting Nicotine Agonists): NNS=Nicotine Nasal Spray NI=Nicotine [Oral] Inhaler NG=Nicotine Gum NL= Nicotine Lozenge. Some patients will need indefinite use of Controller or Reliever Medications to maintain zero nicotine withdrawal symptoms and no cigarette use. ACCP Tobacco-Dependence Treatment Tool Kit, 3rd Ed., 2010 I Copyright 2009-2010 American College of Chest Physicians What s In A Name or a Word? EVERYTHING! Our Name Defines Who We Are A Word May Have Positive or Very Negatively Charged Connotations E.g., Ground Beef, or Pink Slime The Same Holds True for What We Call Stopping Smoking Treating Tobacco Use and Dependence, or Smoking Cessation David P.L. Sachs, MD 27 50

Cessation : Time to Retire It David P.L. Sachs, MD 51 Why Not Smoking Cessation? 1 Smoking Cessation Medically inaccurate, vague term Pejorative term Blames the patient the cigarette user not the pathogen Smoking 1 Focuses on the individual Just say no! Suck it up: Just stop! Is the symptom; not the pathogen causing the behavior 1 Slade J. Cessation: It s Time to Retire the Term. SRNT Newsletter 1999;5(3):1, 4-5. 2 Jason LA, et al. Evaluating Attributions for an Illness Based Upon a Name. Am J Community Psychol 2002;30(1):133-148. 3 Fiore MC, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Dept of Health & Human Services. Public Health Service. May 2008. (www.surgeongeneral.gov/tobacco/default.htm) 4 American College of Chest Physicians. Tobacco-Dependence Treatment Tool Kit, 3rd Ed. Northbrook, IL: ACCP. June 2010. (http://tobaccodependence.chestnet.org) David P.L. Sachs, MD 52 28

Why Not Smoking Cessation? 2 Oh! The Absolute Worst Thing? Nobody can pronounce it correctly! Smoking Sensation Cessation Habit paradigm of tobacco use1 Trivializes the problem2 Ignores the neurobiology of nicotine addiction3,4 1Slade J. Cessation: It s Time to Retire the Term. SRNT Newsletter 1999;5(3):1, 4-5. 2Jason LA, et al. Evaluating Attributions for an Illness Based Upon a Name. Am J Community Psychol 2002;30(1):133-148. 3Fiore MC, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Dept of Health & Human Services. Public Health Service. May 2008. (www.surgeongeneral.gov/tobacco/default.htm) 4American College of Chest Physicians. Tobacco-Dependence Treatment Tool Kit, 3rd Ed. Northbrook, IL: ACCP. June 2010. (http://tobaccodependence.chestnet.org) David P.L. Sachs, MD 53 Why Not Smoking Cessation? 3 Tobacco Dependence3,4 Medically accurate, precise term4 Non-pejorative, non-value-laden term2 Focus on the genetic and sub-cellular basis Characteristic of all chronic medical diseases Drives the behavior Cessation 1 An event (not a process) Not a clinical activity Treatment of tobacco dependence1,3,4 A clinical activity A process (not an event) 1Slade J. Cessation: It s Time to Retire the Term. SRNT Newsletter 1999;5(3):1, 4-5. 2Jason LA, et al. Evaluating Attributions for an Illness Based Upon a Name. Am J Community Psychol 2002;30(1):133-148. 3Fiore MC, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Dept of Health & Human Services. Public Health Service. May 2008. (www.surgeongeneral.gov/tobacco/default.htm) 4American College of Chest Physicians. Tobacco-Dependence Treatment Tool Kit, 3rd Ed. Northbrook, IL: ACCP. June 2010. (http://tobaccodependence.chestnet.org) David P.L. Sachs, MD 29 54

Sign-Up Sheets For my slide-set, including slides I didn t have time to present today, other materials and patient monitoring tools, and notices of future educational training programs to improve your clinical skills to effectively treat tobacco dependence as part of your clinical practice: Enter your» Name» E-Mail» Office Phone (I need this if my e-mail to you bounces back as Not Deliverable, so that we can correct your e-mail address) On 1 of the 20 sheets in this room Please leave these sheets where you found them; I shall collect them during our lunch break. David P.L. Sachs, MD-2/25/2015 Palo Alto Center for Pulmonary Disease Prevention 55 Case #1 Johnny M. Xxx David P.L. Sachs, MD-10/15/2014 Palo Alto Center for Pulmonary Disease Prevention 56 30

Oh, And One More Thing Thank you! SRNT 2015 Pre-Conference Workshop #8 2/57/15 David P.L. Sachs, MD 57 31